ADVENTRX Announces Conference Call To Review Protocol For Phase 3
Clinical Study Of ANX-188
SAN DIEGO, Oct. 23, 2012 /PRNewswire/ -- ADVENTRX
Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that it will
hold a conference call at 4:30 p.m. Eastern
Time, 1:30 p.m. Pacific Time
on Thursday, October 25, 2012
to review the protocol for its upcoming phase 3 clinical study
of ANX-188 (purified poloxamer 188) in sickle cell disease, which
is planned to begin this quarter.
(Logo:
http://photos.prnewswire.com/prnh/20120612/LA22456LOGO-a)
Interested parties may access the conference call by dialing
(800) 860-2442 from the U.S. and (412) 858-4600 from outside the
U.S. and should request the ADVENTRX Pharmaceuticals, Inc. Call.
The webcast will be available live via the Internet by accessing
the Investors section of ADVENTRX's website at
http://ir.adventrx.com. Replays of the webcast will be available on
the Company's website for 30 days and a phone replay will be
available through November 1, 2012 by
dialing (877) 344-7529 from the U.S. and (412) 317-0088 from
outside the U.S. and entering conference reference number
10019681.
About ADVENTRX Pharmaceuticals
ADVENTRX
Pharmaceuticals is a biopharmaceutical company developing
proprietary product candidates to treat various diseases and
conditions. The Company's lead product candidate, ANX-188, has
potential to reduce ischemic tissue injury and end-organ damage by
restoring microvascular function which is compromised in a wide
range of serious and life-threatening diseases and
conditions. The Company initially is developing ANX-188 as a
treatment for complications arising from sickle cell disease. More
information can be found on the Company's web site at
www.adventrx.com.
SOURCE ADVENTRX Pharmaceuticals, Inc.